Kura Oncology Inc (NAS:KURA)
$ 8.86 -0.08 (-0.89%) Market Cap: 688.99 Mil Enterprise Value: 250.32 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 29/100

Kura Oncology Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript

May 30, 2023 / 05:30PM GMT
Release Date Price: $13.21 (-1.05%)
Phil Nadeau
Cowen and Company, LLC - Analyst

Good afternoon, and welcome once again to Cowen and Company's Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to moderate the discussion with Troy Wilson, the President and CEO of Kura.

Questions & Answers

Phil Nadeau
Cowen and Company, LLC - Analyst

Troy, some news this morning. Kura's got the abstract accepted at EHA. So maybe we'd start by laying the background and discussing what was presented at ASH. Could you provide some highlights from ziftomenib's ASH presentation as a way of setting the table for the EHA?

Troy Wilson
Kura Oncology, Inc. - President & CEO

Sure. Yes, Phil, happy to do that. And thanks again for the invitation to attend the session. So at ASH 2022, back in December, we presented data from the Phase 1b study for ziftomenib for both NPM1-mutant and KMT2A-rearranged AML patients. Actually, we presented the entirety of the Phase 1 experience, the Phase 1a escalation, and in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot